Recent

% | $
Quotes you view appear here for quick access.

Geron Corporation (GERN) Message Board

earfool 27 posts  |  Last Activity: May 20, 2015 10:10 AM Member since: Feb 22, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    JNJ announes Imetelstat as hope for blockbuster

    by jayfish101 May 20, 2015 9:26 AM
    earfool earfool May 20, 2015 10:10 AM Flag

    Jay nice work on finding this article to share with us.

  • Reply to

    Baker brothers

    by biotechjunkie May 16, 2015 5:42 PM
    earfool earfool May 17, 2015 1:13 PM Flag

    I had to check up on that but ....confirmed.

    Julian C. Baker

    Managing Partner, Baker Brothers Investments

    Julian C. Baker is a Managing Partner of Baker Brothers Investments, which he and his brother, Felix Baker, Ph.D., founded in 2000. Baker Brothers Investments manages long-term investment funds for major university endowments and foundations which are focused on publicly traded life sciences companies. Mr. Baker’s career as a fund manager began in 1994 when he co-founded a biotechnology investing partnership with the Tisch family. Previously, Mr. Baker was employed from 1988 to 1993 by the private equity investment arm of Credit Suisse First Boston Corporation.

  • Reply to

    Primary endpoints of new study

    by biopearl Apr 27, 2015 2:31 PM
    earfool earfool May 15, 2015 10:45 AM Flag

    Jack, right on, I totally agree.

  • Reply to

    Trial Sites....

    by longtimelong1 May 13, 2015 10:01 AM
    earfool earfool May 13, 2015 12:11 PM Flag

    Thank you longtimelong
    Here is the listing of sites

    Locations
    La Jolla, California, United States
    Stanford, California, United States
    Chicago, Illinois, United States
    Baltimore, Maryland, United States
    Rochester, Minnesota, United States
    St. Louis, Missouri, United States
    Bronx, New York, United States
    Durham, North Carolina, United States
    Philadelphia, Pennsylvania, United States
    Dallas, Texas, United States
    Seattle, Washington, United States
    Antwerpen, Belgium
    Leuven, Belgium
    Angers, France
    Lille, France
    Marseille Cedex 9, France
    Paris, France
    Pierre Benite, Frace
    Toulouse Cedex 9, France
    Aachen, Germany
    Dresden, Germany
    Duesseldorf, Germany
    Frankfurt, Germany
    Koeln, Germany
    Mannheim, Germany
    Muenchen, Germany
    Rostock, Germany
    Chiayi, Taiwan
    Taipei, Taiwan

    Sponsors and Collaborators
    Janssen Research & Development, LLC

    Sentiment: Buy

  • earfool earfool May 7, 2015 9:59 PM Flag

    Thank you Texas.

  • Reply to

    Somethings going on with this stock

    by bigkosh May 7, 2015 9:53 AM
    earfool earfool May 7, 2015 10:19 AM Flag

    There are plenty of shares from sellers to buy for a modest investor like myself. An order of 500 shares to add to my position was filled as soon as I clicked the buy button.

  • Reply to

    Just Checked

    by earfool May 6, 2015 2:11 PM
    earfool earfool May 6, 2015 2:17 PM Flag

    Forgot to mention that approximately 200 participants will be enrolled in this study per the trial page.

  • earfool by earfool May 6, 2015 2:11 PM Flag

    I dropped in just to check out the usual board buzz. It seems very quiet. It has been about a month since the Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor was listed on the gov Clinical Trials page and there is nothing new there.

    There are 11 clinical trial centers (cities) listed so, if equal patients for all sites, that would be about 19 patients apiece for each center. When America and perhaps Israel also are added to the list then maybe it could be down to 5 to 10 patients per clinic so results (CR-PR-CI ) will hopefully cascade in with meteoric speed.

  • Reply to

    $275 after earnings prediction

    by ltgmaster May 6, 2015 8:15 AM
    earfool earfool May 6, 2015 1:57 PM Flag

    Jefferies Starts Tesla With A Buy Rating And $350 Target

  • Reply to

    Influence of this BB

    by shoenfield Apr 16, 2015 4:55 PM
    earfool earfool Apr 17, 2015 10:14 AM Flag

    I've always wondered so turning to the literature there seems to be some evidence that message board sentiment is becoming a variable to be considered. See the below study abstract...

    ...earfool

    Do Internet Stock Message Boards Influence Trading? Evidence from Heavily Discussed Stocks with No Fundamental News

    Sanjiv Sabherwal
    University of Texas at Arlington - Department of Finance and Real Estate
    Salil K. Sarkar
    University of Texas at Arlington
    Ying (Clement) Zhang
    University of Texas at Arlington

    November/December 2011
    Journal of Business Finance & Accounting, Vol. 38, Issue 9‐10, pp. 1209-1237, 2011
    Abstract:

    This study extends the literature on the information content of stock message boards. To better understand the effect of online postings on trading activities and reduce the error due to stocks with small message board followings, we examine stocks with no fundamental news and high message posting activity. Such stocks tend to be of small firms with weak financials. For those stocks, we find a two‐day pump followed by a two‐day dump manipulation pattern among online traders, which **suggests that an online stock message board can be used as a herding device to temporarily drive up stock prices**. We also find that online traders’ credit‐weighted sentiment index, but not the number of postings, is positively associated with contemporaneous return and negatively predicts the return next day and two days later. Also, absolute sentiment is negatively related with contemporaneous and next day's intraday volatility and positively related with the proportion of volume in small‐sized trades.

    ***We conclude that message board sentiment is an important predictor of trading‐related activities.**

  • earfool earfool Apr 14, 2015 11:01 PM Flag

    Interesting summary. Thanks!

  • Reply to

    Why did we give away our stem cell patents

    by hairypotter9 Apr 7, 2015 1:48 PM
    earfool earfool Apr 7, 2015 4:40 PM Flag

    mruyog, How did you come to this knowledge, what is your source, that Huh was mainly responsible for Geron discontinuing the stem cell pipeline? Thanks.

  • earfool earfool Mar 27, 2015 9:37 AM Flag

    Well said ryanvball1 !

  • earfool earfool Mar 27, 2015 9:09 AM Flag

    Those Basket Studies are now possible but only just recently. The evolution of Gene sequencing has been progressing at rocket speed and its data is now solid. Gene sequencing costs have dropped so physicians can routinely look for many cancer-causing mutations in cancerous tumors. It has been found that when drugs are personalized to a patient’s **specific cancer causing gene mutation** many of these basket study drugs can have a response rate of up to 50 or 60 percent.

    Dr. Tefferi and other have talked about looking at specific gene mutations in Myelofibrosis and tailoring treatment to those.

    Mutations in the MPL, CALR, TET2 and JAK2 ** Genes** are associated with most cases of primary myelofibrosis.

    ....earfool

  • Reply to

    8-10%

    by earfool Mar 24, 2015 7:26 PM
    earfool earfool Mar 25, 2015 2:23 PM Flag

    Good enough, I'm encouraged but help me find a Geron or Mayo reference to that please. I've tried to no avail but sometime you just need the right search term combinations.

  • Reply to

    8-10%

    by earfool Mar 24, 2015 7:26 PM
    earfool earfool Mar 24, 2015 11:15 PM Flag

    Can you help me to find a reference to that ligas?

  • Reply to

    8-10%

    by earfool Mar 24, 2015 7:26 PM
    earfool earfool Mar 24, 2015 11:12 PM Flag

    also.... from Seek Alpha

    "Thomas Yip - MLV & Co.

    Okay. And my next question, I know is a little bit early since we’re just looking at starting MF and MDS trials in 2015. But regarding future plans for **AML**, I am just wondering what is the scope and the economics of potentially expanding into AML?

    John Scarlett - President and CEO

    Thomas, this is Chip. The agreement with Janssen contemplates two, or specified I should say, two initial studies that are well laid out. The first one is the Phase 2 MF study. The second is the Phase 2 MDS study, both of which we expect to initiate this year.
    Beyond that although **AML** as you point out is referred to in the CDP, etcetera there are (no specificity) around that....................."

  • Reply to

    8-10%

    by earfool Mar 24, 2015 7:26 PM
    earfool earfool Mar 24, 2015 11:09 PM Flag

    I've been booted off a few times by Yahoo so will try again here

    To my understanding. There was only preclinical non-human data presented at ASH and Tefferi’s abstract did not mention AML.

    I remember back in 2010 GRNVAC1 Vaccination was Associated with Prolonged Disease-Free Survival in Selected Patients with High-Risk AML in a phase two study….Geron was to work on GRNVAC2 but it did not happen.

    Development of *specifically” imetelstat for AML was in a recent release saying it will proceed under a mutually agreed clinical development plan, which is expected to include Phase 2 studies in MF and MDS as initial studies, additional registration studies in MF and MDS, and exploratory Phase 2 and potential follow-on Phase 3 studies in AML.

  • earfool by earfool Mar 24, 2015 7:26 PM Flag

    I think it bears mentioning that AML is **not just** a transformation of MF but in addition approximately 8-10% of all patients treated for other cancers will develop AML an average of 5 years after receiving treatment. The average life expectancy after diagnosis is reportedly a scant *eight* months. (Thus. I await any data on AML treated with Imetelstat related to survival time)

    ....earfool

  • Reply to

    Re MEIP

    by biopearl Mar 23, 2015 3:10 PM
    earfool earfool Mar 23, 2015 3:19 PM Flag

    Thanks bio, I missed that but only became aware of MEIP after some posters here were talking about it a few weeks ago.

    My condolences to any Meip investors here.

GERN
3.95-0.07(-1.74%)May 22 4:00 PMEDT